Daniel Lynch, MBA

Executive Chairman of the Board

Daniel Lynch is a venture partner at Third Rock Ventures and is the executive chairman of Proclara’s board of directors. Previously, he served as chief executive and chief financial officer of ImClone Systems Corporation. As ImClone's chief executive officer, he led ImClone through a significant turnaround, helping to restore the company's reputation and to secure FDA approval of ERBITUX (Cetuximab), a novel cancer treatment. As its chief financial officer, Lynch led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, Lynch served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. Lynch received his Bachelor of Arts in mathematics from Wesleyan University and his Master of Business Administration from the Darden Graduate School of Business Administration at the University of Virginia.

In addition to chairing Proclara’s board, Lynch is chairman of the board of the following companies: bluebird bio, Blueprint Medicines, RaNA Therapeutics, BIND Therapeutics and Eleven Biotherapeutics. Lynch has advised and served as chairman of the board of directors for a number of biopharmaceutical companies, which include Stromedix, Inc. (until its acquisition by Biogen Idec in 2012) and Avila Therapeutics (until its acquisition by Celgene Corporation in 2012). He was also a member of the board of directors and the audit committee of U.S. Oncology for five years until 2010, when it was acquired by McKesson.